Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 41234

Novartis to Drop Anti-Infectives Research Programs

The Novartis Institutes for BioMedical Research is ending its early-stage anti-infectives research programs located in Emeryville, Calif. As a result, the company expects to lay off about 140 employees.

Read More »

Regulus Therapeutics Slashes 60 Percent of Workforce

Regulus Therapeutics announced a corporate restructuring that included the termination of 60 percent of the company’s workforce, which caused a massive stock plummet.

Read More »

OxyContin Maker Purdue Pharma to Cut 350 More Jobs

Purdue Pharma, which sells the painkiller OxyContin, announced that the company laid off approximately 350 staffers.

Read More »

Intarcia Pink Slips 60 Employees, Ends Studies

Boston-based Intarcia Therapeutics undertook a restructuring that includes the termination of up to 60 employees and the closing of two programs.

Read More »

Pernix Cuts 22 Percent of Workforce in Reorganization

Pernix Therapeutics is undergoing a reorganization that includes the termination of a number of sales representatives.

Read More »

Allergan to Slash 1,000+ Jobs

Allergan will cut 1,000 positions, about 5 percent of its workforce, as the company looks to cut costs.

Read More »

Teva Cuts 14,000 Jobs in Massive Reorganization

Teva Pharmaceutical announced a comprehensive restructuring plan that includes the elimination of 25 percent of the company’s global workforce.

Read More »

Depomed Pink Slips 40 Percent of Staff

Depomed Inc. is looking to relocate its headquarters from the Bay Area after inking a deal with Collegium Pharmaceutical Inc.

Read More »

Troubled Otonomy Cuts Jobs

Otonomy, which develops innovative therapeutics for diseases and disorders of the ear, is initiating more job cuts as well as planning to divest one of its assets.

Read More »

Mylan Chops Another 200 to 300 Jobs

Mylan reportedly let go between 200 and 300 people from its West Virginia operations.

Read More »

Layoffs in California: Amgen to Slash 200 R&D Jobs, Genentech to Cut 130

Roche company Genentech indicated it is laying off 130 people at its facility in Vacaville, Calif. by the end of 2017. Amgen is reportedly eliminating about 200 R&D jobs, mostly in California, by the end of 2017.

Read More »

Bio-Rad to Shut Down Cambridge R&D Site

California-based Bio-Rad is shuttering a research and development facility in the white-hot biotech hub of Cambridge, Mass.

Read More »

Quest Diagnostics to Pink Slip 538 Shiel Medical Laboratory Employees

Shiel Medial Laboratory will terminate 538 employees at a New Jersey facility following the company’s acquisition by Quest Diagnostics. The layoffs were announced one day after Quest’s acquisition was announced.

Read More »

Mateon Therapeutics Cuts 60 Percent of Jobs

Following a failure to determine clear efficacy in its experimental combo ovarian cancer drug, Mateon ended the drug program and cut 60% of its employees.

Read More »

Genocea Shifts R&D Focus in Restructuring

Genocea Biosciences is pivoting a development strategy to focus on development of neoantigen cancer treatments and scrapping its Phase III-ready herpes drug.

Read More »

Nestle to cut jobs at French skin health R&D center

Nestle plans to cut up to 450 jobs at a Galderma research and development center in southern France, the Swiss company said.

Read More »

Otonomy Slashes Staff After Failed Phase III Study

Otonomy is cutting jobs and slashing operations in order to stay in business.

Read More »

Lilly Cuts 3,500 Jobs, Shuts Down 2 R&D Sites

Eli Lilly and Company announced the company plans to cut 3,500 jobs. The majority of the job cuts will be in the U.S., and include voluntary early retirement programs.

Read More »

Bristol-Myers Squibb Plans Layoffs In 2017

As Bristol-Myers Squibb’s HIV drugs Reyataz and Sustiva lose patent protection, the company plans to lay off 58 staffers in October 2017.

Read More »

Takeda Axes Sales Jobs, Forces Hundreds of Employees to Relocate to Boston

July 18, 2017 By Mark Terry, Breaking News Staff Chicago, Ill. – Takeda Pharmaceuticals (TKPYY) is shifting hundreds of executives from the Chicago area to relocate to Boston. It is also cutting hundreds of field sales positions throughout the U.S.   In March, the company indicated it was making job cuts in the Cambridge, […]

Read More »

Page 1 of 41234

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2018 Focus: Biotech, Payer Access, DTC and more!


Ad Right Bottom

Main Navigation